Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis
Authors:
Open Access
- 14 February 2020
- journal article
- review article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-7
Abstract
In the last few years, V-domain Ig-containing suppressor of T cell activation(VISTA) has been reported as a prognostic biomarker in articles including various solid tumours. However, their conclusions have been controversial. For this reason, we performed this meta-analysis to further verify the prognostic value of VISTA in solid tumours. All relevant literature was identified from PubMed, Embase, the Cochrane Library and Web of Science. Ten studies, including 2, 440 patients, were eligible for the analysis. The pooled results showed that high expression of VISTA was associated with favourable overall survival (OS) than that seen with low expression of VISTA (7 studies, hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66–0.86, P < 0.001). In addition, high expression of VISTA significantly correlated with high numbers of CD8 (+) tumour infiltrating lymphocytes (TILs) (3 studies, risk ratio (RR) = 1.80, 95% CI: 1.41–2.31, P < 0.001). In conclusion, these results indicate that VISTA is a potential prognostic biomarker in solid tumours.Keywords
Funding Information
- National Natural Science Foundation of China (81772896,81630025,81602383)
This publication has 30 references indexed in Scilit:
- The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinomaOncoImmunology, 2019
- VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinomaBMC Cancer, 2018
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian CancerJAMA Oncology, 2017
- High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinomaMedicine, 2017
- Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinomaCancer Immunology, Immunotherapy, 2017
- Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinomaHead & Neck, 2016
- VISTA Is an Immune Checkpoint Molecule for Human T CellsCancer Research, 2014
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007